IDEXX Laboratories
IDXX (NASDAQ)
IDEXX Laboratories is consistently featured on ESG stock lists for U.S. investors, thanks to its strong diagnostics business and high ESG ratings. Despite a challenging year, with a 1-year return of -1.35% and a 5-year return of -18.65%, analysts maintain a positive outlook, assigning a median 12-month price target of $775, while forecasting a robust earnings growth of 12.2% for the current fiscal year.
Pros:
- Strong ESG ratings
- Diverse diagnostics business
Cons:
- Negative returns over the past five years
- Market volatility risk
IDEXX Laboratories (IDXX) may be suitable for investors looking for exposure to the healthcare sector, particularly those interested in companies with strong ESG credentials. While the stock has experienced recent underperformance, the positive analyst outlook and anticipated earnings growth could appeal to long-term investors willing to weather short-term volatility.